| 000 | 01774 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518014359.0 | ||
| 264 | 0 | _c20200430 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1440-1797 | ||
| 024 | 7 |
_a10.1111/nep.13554 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRamachandran, Raja | |
| 245 | 0 | 0 |
_aPersistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. _h[electronic resource] |
| 260 |
_bNephrology (Carlton, Vic.) _cDec 2019 |
||
| 300 |
_a1241-1247 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntigens, CD19 _xanalysis |
| 650 | 0 | 4 |
_aCalcineurin Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlomerulosclerosis, Focal Segmental _xcomplications |
| 650 | 0 | 4 |
_aGlucocorticoids _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 | _aIndia |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNephrosis, Lipoid _xcomplications |
| 650 | 0 | 4 |
_aNephrotic Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBharati, Joyita | |
| 700 | 1 | _aRao, Indu | |
| 700 | 1 | _aKashif, Ahmed W | |
| 700 | 1 | _aNada, Ritambhra | |
| 700 | 1 | _aMinz, Ranjana | |
| 700 | 1 | _aGupta, Krishan L | |
| 700 | 1 | _aKohli, Harbir S | |
| 773 | 0 |
_tNephrology (Carlton, Vic.) _gvol. 24 _gno. 12 _gp. 1241-1247 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/nep.13554 _zAvailable from publisher's website |
| 999 |
_c29198533 _d29198533 |
||